Piper Sandler initiated coverage of Corcept Therapeutics with an Overweight rating and $27 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics announces preliminary results of tender offer
- Corcept Therapeutics initiates CATALYST clinical trial
- Corcept Therapeutics Initiates CATALYST Clinical Trial
- Corcept Therapeutics price target lowered to $32 from $33 at Canaccord
- Corcept Therapeutics commences tender offer to purchase 7.5M shares